De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Sage Therapeutics Dividend
Dividend criteriumcontroles 0/6
Sage Therapeutics does not have a record of paying a dividend.
Belangrijke informatie
n/a
Dividendrendement
n/a
Uitbetalingsratio
Gemiddelde opbrengst industrie | 1.9% |
Volgende betaaldatum dividend | n/a |
Ex-dividenddatum | n/a |
Dividend per aandeel | n/a |
Winst per aandeel | -US$7.30 |
Dividendrendementsvoorspelling | 0% |
Recente dividendupdates
Geen updates
Recent updates
Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge
Aug 30Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade)
Jul 25Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price
Jul 13Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data
May 30Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?
May 21Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%
Feb 22Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)
Feb 15Sizing Up Sage Therapeutics
Jan 22Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade
Aug 09Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Feb 22An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued
Nov 12Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Oct 14Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M
Aug 02We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Jun 15Sage Therapeutics: Well-Funded But Uninspiring Data
Mar 24We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Feb 26Sage Therapeutics: Biogen's Backing May See It Through
Jan 04What You Need To Know About The Sage Therapeutics, Inc. (NASDAQ:SAGE) Analyst Downgrade Today
Aug 05Sage Therapeutics: Showing Upside, But There Are Plenty Of Unknowns
Jul 25Sage Therapeutics Needs To Show Improved Data To Regain Investor Trust
Jul 12Stabiliteit en groei van betalingen
Dividenden ophalen
Stabiel dividend: Insufficient data to determine if SAGE's dividends per share have been stable in the past.
Groeiend dividend: Insufficient data to determine if SAGE's dividend payments have been increasing.
Dividendrendement versus markt
Sage Therapeutics Dividendrendement versus markt |
---|
Segment | Dividendrendement |
---|---|
Bedrijf (SAGE) | n/a |
Markt onderkant 25% (US) | 1.4% |
Markt Top 25% (US) | 4.3% |
Gemiddelde industrie (Biotechs) | 1.9% |
Analist prognose (SAGE) (tot 3 jaar) | 0% |
Opmerkelijk dividend: Unable to evaluate SAGE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Hoog dividend: Unable to evaluate SAGE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Winstuitkering aan aandeelhouders
Verdiendekking: Insufficient data to calculate SAGE's payout ratio to determine if its dividend payments are covered by earnings.
Contante uitbetaling aan aandeelhouders
Kasstroomdekking: Unable to calculate sustainability of dividends as SAGE has not reported any payouts.